Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Preaxia Health Care Payment Systems (PAXH) Shares Outstanding (Diluted Average) (2022 - 2025)

Preaxia Health Care Payment Systems' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $39.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 98.31% to $39.2 million in Q4 2025 year-over-year; TTM through Nov 2025 was $39.2 million, a 98.31% increase, with the full-year FY2025 number at $19.8 million, changed 0.0% from a year prior.
  • Shares Outstanding (Diluted Average) hit $39.2 million in Q4 2025 for Preaxia Health Care Payment Systems, up from $19.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for PAXH hit a ceiling of $39.2 million in Q4 2025 and a floor of $19.8 million in Q2 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $21.1 million across 4 years, with a median of $19.8 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): changed 0.0% in 2023 and later skyrocketed 98.31% in 2025.
  • Tracing PAXH's Shares Outstanding (Diluted Average) over 4 years: stood at $19.8 million in 2022, then changed by 0.0% to $19.8 million in 2023, then changed by 0.0% to $19.8 million in 2024, then surged by 98.31% to $39.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for PAXH at $39.2 million in Q4 2025, $19.8 million in Q3 2025, and $19.8 million in Q2 2025.